首页> 外文期刊>Journal of endourology >A multi-institutional study on the safety and efficacy of specimen morcellation after laparoscopic radical nephrectomy for clinical stage T1 or T2 renal cell carcinoma.
【24h】

A multi-institutional study on the safety and efficacy of specimen morcellation after laparoscopic radical nephrectomy for clinical stage T1 or T2 renal cell carcinoma.

机译:腹腔镜根治性肾切除术后标本粉碎的安全性和有效性的多机构研究,用于临床T1或T2期肾细胞癌。

获取原文
获取原文并翻译 | 示例
       

摘要

INTRODUCTION AND OBJECTIVE: Specimen morcellation during laparoscopic radical nephrectomy (LRN) for renal cell carcinoma (RCC) is controversial. We seek to evaluate the safety and efficacy of specimen morcellation and LRN for treatment of presumed malignant renal lesions. METHODS: We retrospectively reviewed all patients who underwent LRN at three academic institutions from 1996 to 2007. One hundred eighty-eight patients underwent specimen morcellation after LRN for enhancing solid or cystic renal masses. RESULTS: LRN was successfully performed on all the patients. Patient age ranged from 36 to 94. One hundred sixty-seven patients were in clinical stage T1, 19 patients T2, and unknown in two. The specimen was manually morcellated within a Cook Lap Sac or Endocatch II bag under laparoscopic or direct observation. On histological review of morcellated specimens, 165 patients were confirmed to have RCC, 17 had an oncocytoma, and 2 had benign cysts. At least 13 patients with RCC were pathologically upgraded to stage T3. Mean operative time was 225 minutes (range 94-650). Mean hospital stay was 2.5 days (range 1-8). In patients with RCC, 11 developed recurrent disease with mean follow-up of 21 months (range 0.3-111). In one patient, a port site recurrence occurred in concert with renal fossa and lymph node metastases. CONCLUSIONS: Intracorporeal mechanical morcellation after LRN appears to be safe and effective in clinical stage T1 and T2 RCC. This supports the use of morcellation as an alternative for intact specimen removal in properly selected patients.
机译:引言和目的:腹腔镜根治性肾切除术(LRN)肾细胞癌(RCC)期间的标本粉碎是有争议的。我们寻求评估标本粉碎和LRN治疗假定的恶性肾脏病变的安全性和有效性。方法:我们回顾性研究了1996年至2007年间在三所学术机构接受LRN的所有患者。188例LRN后接受了标本粉碎以增强实体或囊性肾脏肿块的患者。结果:所有患者均成功进行了LRN。患者年龄从36岁到94岁不等。167例患者处于临床T1阶段,19例患者T2在两个阶段中未知。在腹腔镜或直接观察下,将样品在Cook Lap Sac或Endocatch II袋中手动粉碎。在对有组织的标本进行组织学检查时,证实有165例患者患有RCC,17例患有肿瘤细胞瘤,2例患有良性囊肿。至少有13例RCC患者在病理上升级为T3期。平均手术时间为225分钟(范围94-650)。平均住院时间为2.5天(范围1-8)。在RCC患者中,有11例复发性疾病,平均随访21个月(范围0.3-111)。在一名患者中,与肾窝和淋巴结转移一起发生了端口部位复发。结论:LRN后的体内机械粉碎在T1和T2 RCC临床阶段看来是安全有效的。这支持使用切碎术作为适当选择的患者中完整标本去除的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号